Tuesday saw the announcement of two contracts worth a combined $897 million by Samsung Biologics, a South Korean company, to produce goods for Pfizer.

As a result of the most recent agreements, the Samsung Group’s biotech division will create biosimilar goods in South Korea at its new Plant 4 up until 2029, covering everything from immunotherapy to oncology and inflammation.

The most recent orders from Pfizer raise the total amount of orders from this year to $1.08 billion, according to a statement from Samsung Biologics.

A $704 million contract and an extra $193 million order that is a follow-up to a March transaction are among the news made on Tuesday.

Samsung Biologics welcomed the orders as an expansion of a strategic alliance and noted that the total number of contracts it has signed this year has already surpassed that of the previous year.

Samsung Biologics agreed to partnerships with Eli Lilly Kinsale and GlaxoSmithKline earlier this year.

Samsung Biologics said in March that it would devote 2 trillion won ($1.54 billion) to the construction of a new plant in South Korea by September 2025.

(Adapted from Reuters.com)